# Nuclide record idea-rlt-plus-checkpoint-inhibitor (idea). Data CC BY-NC 4.0, attribute "Data from Nuclide (nuclide.cc)". Whole corpus: https://nuclide.cc/api/v1/nuclide.nt
@prefix schema: <https://schema.org/> .
@prefix nuclide: <https://nuclide.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://nuclide.cc/ideas/idea-rlt-plus-checkpoint-inhibitor/>
  a schema:CreativeWork ;
  nuclide:kind "idea" ;
  schema:identifier "idea-rlt-plus-checkpoint-inhibitor" ;
  schema:name "Adding a checkpoint inhibitor to PSMA radioligand therapy"@en ;
  schema:description "Radiation from a targeted radioactive treatment can spill tumour debris that alerts the immune system. Giving an immunotherapy drug at the same time, to stop the immune system being switched off, is being tested to see if it makes the radioactive treatment work better."@en ;
  schema:url <https://nuclide.cc/ideas/idea-rlt-plus-checkpoint-inhibitor/> ;
  schema:dateModified "2026-09-22"^^xsd:date ;
  schema:citation <https://pubmed.ncbi.nlm.nih.gov/41926961/>, <https://www.asco.org/abstracts-presentations/ABSTRACT383277>, <https://www.cancernetwork.com/view/lu-psma-617-pembrolizumab-shows-early-efficacy-in-metastatic-crpc>, <https://clinicaltrials.gov/study/NCT03658447> ;
  nuclide:tag "combination therapy", "immunotherapy", "prostate" ;
  nuclide:related <https://nuclide.cc/drugs/pluvicto/>, <https://nuclide.cc/drugs/pembrolizumab/>, <https://nuclide.cc/people/sandhu-shahneen/>, <https://nuclide.cc/indications/prostate-mcrpc/>, <https://nuclide.cc/trials/vision/>, <https://nuclide.cc/trials/therap/>, <https://nuclide.cc/isotopes/lu-177/> .